Autologous stem-cell transplantation is widely accepted as effective therapy for patients with relapsed aggressive B-cell non-Hodgkin lymphomas. Although 40-60% of younger patients with diffuse large cell lymphoma can expect to be cured, substantial numbers will experience a relapse. In addition, certain histologic subtypes are associated with particularly poor prognoses with combination chemot...

Although the majority of patients with Hodgkin lymphoma attain a complete response with initial combination chemotherapy and/or radiotherapy, 20–40% of patients with newly diagnosed, advanced-stage Hodgkin lymphoma are refractory to initial therapy or relapse following a response.1,2 The optimal second-line treatment approach for these patients is high-dose chemotherapy followed by autologous s...

non hodgkin lymphomas (nhl) are nodal or extra nodal monoclonal infiltrations by malignant lymphoid cells (b lymphocytes in 80% of cases), which are distinguished as indolent or aggressive forms. according to the heterogeneity of lymphoid cells and their ubiquitous anatomical distribution, these disorders can develop in any organ and have very heterogeneous clinical expressions, but they are us...